C
AbbVie Inc. ABBV
$142.39 $3.892.81%
Recommendation
Hold
Prev Close
$138.50
Volume
9,296,958
Avg Vol (90D)
4,760,386
Market Cap
$244.53B
Dividend & Yield
$5.92(4.27%)
52-Week Range
$130.96 - $168.11
P/E (TTM)
37.92
EPS (TTM)
$3.65
My Lists My Alerts
Report
Rating
Reward
B-
Good
Risk
C-
Fair
Rating Factors
Growth Index
Weak
Efficiency Index
Excellent
Solvency Index
Good
Total Return Index
Fair
Volatility Index
Fair
Dividend Index
Good
Headlines
AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology
11/30/2023 - SeekingAlpha
Maintaining Hold on ImmunoGen Amid AbbVie Acquisition Offer
11/30/2023 - TipRanks Financial Blog
AbbVie's $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained
11/30/2023 - SeekingAlpha
ImmunoGen stock nearly doubled on Thursday: what happened?
11/30/2023 - Invezz News
FLC Capital Advisors Reduces Stock Position in AbbVie Inc. (NYSE:ABBV)
11/30/2023 - Ticker Report
AbbVie to spend $10.1B to acquire ImmunoGen
11/30/2023 - Bizjournals.com - Health Care News
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
11/30/2023 - CNBC: Healthcare
AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio
11/30/2023 - Yahoo! Finance: News
AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio
11/30/2023 - Investopedia Headlines
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
11/30/2023 - Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
11/30/2023 - InvestorPlace
AbbVie to spend $10.1B to acquire ImmunoGen, 43-year-old Waltham biotech
11/30/2023 - BizJournals.com - Nat'l Business News
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
11/30/2023 - Yahoo! Finance: News
Health Care Company AbbVie Announces Acquisition of Immunogen
11/30/2023 - Benzinga
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
11/30/2023 - Zacks Investment Research
AbbVie: Get Ready For More Painful Downside
11/30/2023 - SeekingAlpha
AbbVie: Get Ready For More Painful Downside
11/30/2023 - Seeking Alpha - Long Ideas
Morning Brew: AbbVie Acquires Immunogen in $10B Deal, Salesforce Soars on Earnings
11/30/2023 - GuruFocus
M & A News: AbbVie's (NYSE:ABBV) $10.1B Gamble on ImmunoGen Sends Shares Soaring
11/30/2023 - TipRanks Financial Blog
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
11/30/2023 - FiercePharma
ImmunoGen Stock Soars 80% on AbbVie's $10.1 Billion Takeover
11/30/2023 - Yahoo! Finance: News
Pharmaceutical company AbbVie buying ImmunoGen in $10.1 billion deal
11/30/2023 - Yahoo! Finance: News
AbbVie Should Consider a Dividend Cut -- Here's Why
11/30/2023 - Fool.com Headlines
US Futures Rise As November Surge Closes Strong, Oil Jump Ahead Of Fresh OPEC+ Output Cut
11/30/2023 - Zero Hedge
AbbVie to Buy ImmunoGen for More Than $10 Billion
11/30/2023 - Yahoo! Finance: News
Income Statement
Total Revenue (TTM)
$55.14B
EBITDA (TTM)
$25.94B
EBIT (TTM)
$17.16B
Net Income (TTM)
$6.51B
Balance Sheet
Total Assets (Q)
$136.22B
Total Debt (Q)
$61.18B
Total Liabilities (Q)
$124.09B
Book Value Per Share (Q)
$6.85
Cash Flow
Cash from Operations (TTM)
$25.51B
Cash from Investing (TTM)
-$1.66B
Cash from Financing (TTM)
-$22.41B
Net Change in Cash (TTM)
$1.46B
Filings
Filing Date
Monday, November 6, 2023
Period Date
Saturday, September 30, 2023
Next Filing
Week of Feb 12 and 16 (est)
Price History
Loading...
Beta
0.15
7-Day Total Return
0.26%
30-Day Total Return
-7.11%
60-Day Total Return
-4.81%
90-Day Total Return
-2.11%
Year to Date Total Return
-15.19%
1-Year Total Return
-14.53%
2-Year Total Return
21.93%
3-Year Total Return
36.92%
5-Year Total Return
59.49%
52-week Low
Jun 28, 2023 - $130.96
52-week High
Jan 06, 2023 - $168.11
Valuation
Market Cap
$244.53B - Mega Cap
Enterprise Value
$292.45B
Price/Sales (TTM)
4.45
Price/Book (Q)
20.22
Dividends and Shares
Shares Outstanding
1.77B
Dividend Per Share (Most Recent)
$1.48
Dividend Per Share (TTM)
$5.92
Corporate Info
Website
www.abbvie.com
Phone Number
847 932 7900
Address
1 North Waukegan Road
North Chicago, IL 60064-6400
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases... more
NYSE 11/30/2023 4:00PM Eastern Quotes delayed
Weiss Ratings